| Author (Corporate) | European Commission: DG Communication |
|---|---|
| Series Title | Press Release |
| Series Details | IP/10/8 (7.1.10) |
| Publication Date | 07/01/2010 |
| Content Type | News |
|
The European Commission has opened a formal antitrust investigation into the international pharmaceutical undertaking Lundbeck to examine potential breaches of EU rules on restrictive business practices and on the abuse of a dominant market position under Articles 101 and 102 of the Treaty on the Functioning of the European Union (TFEU). The Commission in particular intends to investigate unilateral behaviour and agreements by Lundbeck which may hinder the entry of generic citalopram into markets in the European Economic Area. Citalopram, originally developed by Lundbeck, is an anti-depressant drug known as a selective serotonin reuptake inhibitor (SSRI). |
|
| Source Link | Link to Main Source http://europa.eu/rapid/pressReleasesAction.do?reference=IP/10/8&format=HTML&aged=0&language=EN&guiLanguage=en |
| Related Links |
|
| Subject Categories | Internal Markets |
| Countries / Regions | Europe |
